Cancer Tumor Profiling Market by Technology [Next-generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), (Fluorescence In Situ Hybridization (FISH) and Chromogenic in Situ Hybridization (CISH)), Microarray, and Others], Technique (Genomics, Proteomics, Epigenetics, and Metabolomics), and Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, and Research Applications) - Global Opportunity Analysis and Industry Forecast, 2017-2023
- ALL1530537
- 190 Pages
- August 2017
- Healthcare
Cancer/tumor profiling uses several molecular biology techniques, such as microarray, polymerase chain reaction (PCR), and in situ hybridization (ISH), to provide specific information about genetic and molecular makeup of tumor. It can detect the presence or absence of distinct disease-associated targets that guide medical practitioners in deciding the appropriate course of treatment for patients. In addition, it enables estimating individual patient risk to cancer by performing high throughput genotyping analysis of tumor DNA and predicting the reaction outcome of the therapy.
The global market is driven by increase in adoption of the cancer profiling methods by oncologists, rise in use of cancer biomarkers, surge in prevalence of cancer, and growth in demand for next-generation sequencing technique to meet the demand for cancer profiling. The global cancer/tumor profiling market was valued at $25,318 million in 2016, and is expected to reach $82,447 million by 2023, registering a CAGR of 18.4% from 2017 to 2023.
The global cancer/tumor profiling market is segmented on the basis of technology, technique, application, and region. Based on technology, it is classified into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarray, and others. The in-situ hybridization segment is further categorized into fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). Based on technique, it is divided into genomics, proteomics, epigenetics, and metabolomics. Based on application, it is classified into personalized medicine, diagnostics, biomarker discovery, prognostics, and research applications. The biomarker discovery segment generated the highest revenue in 2016, registering a CAGR of 17.4% from 2017 to 2023, and is anticipated to continue its dominance throughout the forecast period, owing to growth in demand for biomarkers. However, the personalized medicine segment is expected to witness the highest growth rate in the global market.
Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In the recent years, Asia-Pacific has witnessed rapid growth in the global, owing to rise in incidence of cancer, and increase in demand for better healthcare services in the developing economies such as India and China. In addition, surge in the number of contract research organizations (CROs) and increase in focus of international players on the emerging markets have supplemented the market growth in Asia-Pacific region.
KEY BENEFITS:
- The study provides an in-depth analysis of the global cancer/tumor profiling market along with the current trends and future estimations to elucidate the imminent investment pockets.
- Comprehensive analyses of the factors that drive and restrict the market growth are provided in the report.
- Comprehensive quantitative analysis of the industry is provided from 2016 to 2023 to assist stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps in understanding the trends in technologies and techniques used across the globe.
- Key market players and their strategies are provided to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
By Technology
- Next-generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)
- Fluorescence in Situ Hybridization (FISH)
- Chromogenic in Situ Hybridization (CISH)
- Microarray
- Others
By Technique
- Genomics
- Proteomics
- Epigenetics
- Metabolomics
By Application
- Personalized Medicine
- Diagnostics
- Biomarker Discovery
- Prognostics
- Research Applications
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Turkey
- Argentina
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Qiagen N.V.
- Roche Molecular Systems Inc. (Roche)
- Abbott Molecular (Abbott Laboratories)
- Illumina Inc.
- NeoGenomics Laboratories
- HTG Molecular Diagnostic
- Genomic Health Inc.
- Hologic Gen-Probe
- BD Biosciences (Beckton Dickinson)
- Siemens Healthineers
The other players in the value chain include (profiles not included in the report)
- Claris Life Sciences
- Personal Genome Diagnostics, Inc.
- Perthera, Inc.
- Foundation Medicine, Inc. V.
- Strand
- ApoCell
- Contextual Genomics
- Agendia
- GenScript
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Rise in the adoption of the cancer profiling methods by oncologists
3.6.1.2. Increase in the use of biomarkers in cancer profiling
3.6.1.3. Increase in the demand for next-generation sequencing technique in cancer profiling
3.6.1.4. Rise in incidence of cancer across the globe
3.6.2. Restraints
3.6.2.1. High monetary investments in the development of biomarkers
3.6.2.2. Dearth of skilled professionals
3.6.3. Opportunities
3.6.3.1. Increasing demand for personalized medicine
CHAPTER 4 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. NEXT-GENERATION SEQUENCING (NGS)
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. POLYMERASE CHAIN REACTION (PCR)
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. IMMUNOHISTOCHEMISTRY (IHC)
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. IN SITU HYBRIDIZATION (ISH)
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.5.1. Fluorescence in Situ Hybridization (FISH)
4.5.1.1. Market Size & Forecast
4.5.2. Chromogenic in Situ Hybridization (CISH)
4.5.2.1. Market Size & Forecast
4.6. MICROARRAY
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
4.7. OTHER TECHNOLOGIES
4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast
CHAPTER 5 CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. GENOMICS
5.2.1. Market size and forecast
5.3. PROTEOMICS
5.3.1. Market size and forecast
5.4. EPIGENETICS
5.4.1. Market size and forecast
5.5. METABOLOMICS
5.5.1. Market size and forecast
CHAPTER 6 CANCER/TUMOR PROFILING MARKET, BY APPLICATION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. PERSONALIZED MEDICINE
6.2.1. Market size and forecast
6.3. DIAGNOSTICS
6.3.1. Market size and forecast
6.4. BIOMARKER DISCOVERY
6.4.1. Market size and forecast
6.5. PROGNOSTICS
6.5.1. Market size and forecast
6.6. RESEARCH APPLICATIONS
6.6.1. Market size and forecast
CHAPTER 7 CANCER/TUMOR PROFILING MARKET, BY GEOGRAPHY
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Mexico market size and forecast
7.2.3.3. Canada market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.3.1. UK market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. Germany market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Australia market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.3.1. Brazil market size and forecast
7.5.3.2. Argentina market size and forecast
7.5.3.3. Turkey market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. QIAGEN N.V.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments
8.2. ROCHE MOLECULAR SYSTEMS INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments
8.3. ABBOTT LABORATORIES
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. ILLUMINA INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. NEOGENOMICS LABORATORIES
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments
8.6. HTG MOLECULAR DIAGNOSTIC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments
8.7. GENOMIC HEALTH INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. HOLOGIC GEN-PROBE
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments
8.9. BD BIOSCIENCES (BECKTON DICKINSON)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. SIEMENS HEALTHINEERS
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 2. GLOBAL CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION (PCR), BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET FOR IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2016-2023 ($MILLION)
TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION (ISH), BY REGION, 2016-2023 ($MILLION)
TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET FOR MICROARRAY, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET FOR GENOMICS, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET FOR PROTEOMICS, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET FOR EPIGENETICS, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET FOR METABOLOMICS, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2016-2023 ($MILLION)
TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE. NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 26. EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 28. EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 29. EUROPE CANCER VACCINES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 30. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34. LAMEA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 35. LAMEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 36. LAMEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 37. LAMEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38. QIAGEN: COMPANY SNAPSHOT
TABLE 39. QIAGEN: OPERATING SEGMENTS
TABLE 40. ROCHE: COMPANY SNAPSHOT
TABLE 41. ROCHE: OPERATING SEGMENTS
TABLE 42. ABBOTT: COMPANY SNAPSHOT
TABLE 43. ABBOTT: OPERATING SEGMENTS
TABLE 44. ILLUMINA: COMPANY SNAPSHOT
TABLE 45. ILLUMINA: OPERATING SEGMENTS
TABLE 46. NEOGENOMICS: COMPANY SNAPSHOT
TABLE 47. ADURO: OPERATING SEGMENTS
TABLE 48. HTG: COMPANY SNAPSHOT
TABLE 49. HTG: OPERATING SEGMENTS
TABLE 50. GENOMIC HEALTH: COMPANY SNAPSHOT
TABLE 51. GENOMIC HEALTH: OPERATING SEGMENTS
TABLE 52. HOLOGIC: COMPANY SNAPSHOT
TABLE 53. HOLOGIC: OPERATING SEGMENTS
TABLE 54. BD: COMPANY SNAPSHOT
TABLE 55. BD: OPERATING SEGMENTS
TABLE 56. SIEMENS: COMPANY SNAPSHOT
TABLE 57. SIEMENS: OPERATING SEGMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL CANCER/TUMOR PROFILING MARKET, 2016-2023
FIGURE 2. SEGMENTATION OF CANCER/TUMOR PROFILING MARKET
FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL CANCER/TUMOR PROFILING MARKET
FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 7. BARGAINING POWER OF BUYERS
FIGURE 8. BARGAINING POWER OF SUPPLIERS
FIGURE 9. THREAT OF NEW ENTRANTS
FIGURE 10. THREAT OF SUBSTITUTION
FIGURE 11. COMPETITIVE RIVALRY
FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL CANCER/TUMOR PROFILING MARKET
FIGURE 13. U.S. CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 16. UK CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 17. FRANCE CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 18. GERMANY CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 19. ITALY CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 20. SPAIN CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 24. INDIA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE. AUSTRALIA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 27. BRAZIL CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 28. ARGENTINA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 29. TURKEY CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 32. QIAGEN: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. QIAGEN: REVENUE BY SEGMENT, 2016 (%)
FIGURE 34. QIAGEN: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 35. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. ROCHE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 37. ROCHE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 38. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 39. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 40. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 41. ILLUMINA: NET SALES, 2014-2016 ($MILLION)
FIGURE 42. ILLUMINA: REVENUE BY SEGMENT, 2016 (%)
FIGURE 43. ILLUMINA: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 44. NEOGENOMICS: NET SALES, 2014-2016 ($MILLION)
FIGURE 45.NEOGENOMICS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 46. NEOGENOMICS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 47. HTG: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. HTG: REVENUE BY SEGMENT, 2016 (%)
FIGURE 49. HTG: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 50. GENOMIC HEALTH: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. GENOMIC HEALTH: REVENUE BY SEGMENT, 2016 (%)
FIGURE 52. GENOMIC HEALTH: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 53. HOLOGIC: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. HOLOGIC: REVENUE BY SEGMENT, 2016 (%)
FIGURE 55. HOLOGIC: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 56. BD: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. BD: REVENUE BY SEGMENT, 2016 (%)
FIGURE 58. BD: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 59. SIEMENS: NET SALES, 2014-2016 ($MILLION)
FIGURE 60. SIEMENS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 61. SIEMENS: REVENUE BY GEOGRAPHY, 2016 (%)
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
